glp-1 receptor agonists effectiveness comparison GLP1 vs SGLT2-I in Preventing CKD in T2DM: An Interview – AJKD Blog Clinical efficacy results from clinical

The REWIND trial included patients with hemoglobin A1c levels of up to 9.5%, thus the influence of dulaglutide on glycemic control may underlie the reduced risk of cognitive dysfunction

Importantly, no limiting side effects were recorded (48), providing proof of concept in 2002 for GLP-1 therapy in subjects with T2D

This happens to some GLP-1 users who get full fast and might not eat enough food to get all the protein their body needs, causing a problem: losing valuable muscle along with fat

PMC 304885

Micronutrient and nutritional deficiencies associated with GLP-1 receptor agonist therapy: a narrative review

However, larger RCTs are required in pediatric MASLD comparing the type of physical exercise, are required to help guide management better